Context Therapeutics

CNTX on Nasdaq. Market value $17m.

Watch this stockFree. We tell you when something changes.

Should I look at this?

Look carefully before going further

Why it could be worth it

Nothing stands out yet.

Read the warning sign in its own filings

This is not advice.

Compare with another stock

Who owns it

None of the long-term investors we follow own it. 79 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

7 investors own more than 5%.

  • at least 8.7%−1.2 pts
    (filed with 5 related holders)
    Since 31 March 2026
  • Deep Track Capital, LP
    Passive investor
    at least 8.3%
    (filed with 2 related holders)
    Since 31 March 2025
  • Soleus Capital Master Fund, L.P.
    Passive investor
    at least 7.6%+2.4 pts
    (filed with 5 related holders)
    Since 31 March 2026
  • BlackRock, Inc.
    Passive investor
    6.7%
    Since 30 June 2026
  • Franklin Advisers, Inc.
    Passive investor
    5.3%
    Since 31 December 2024
  • at least 3.3%−2.4 pts
    (filed with 2 related holders)
    Since 30 June 2026
  • at least 2.4%−2.7 pts
    (filed with 2 related holders)
    Since 31 March 2026
  • Avidity Master Fund LP
    Passive investor
    Sold down below 5%
    Since 30 September 2025
  • Franklin Resources, Inc.
    Passive investor
    Sold down below 5%
    Since 31 March 2025
  • Sold down below 5%
    Since 30 June 2026
  • Martin Lehr
    Passive investor
    Sold down below 5%
    Since 31 December 2024
  • MPM BioImpact LLC
    Passive investor
    Sold down below 5%
    Since 30 June 2026
  • David Witzke
    Passive investor
    Sold down below 5%
    Since 31 December 2024
  • Opaleye Management Inc.
    Passive investor
    Sold down below 5%
    Since 31 December 2024

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought or sold on the open market in the last 12 months.

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

1 serious warning sign in Context Therapeutics’ filings.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 23 Mar 2026, plus the 10-Q filed 10 Nov 2026 and 8 later 8-Ks.

  • Doubt it can keep going

    Serious

    The company or its auditor warned it may not have enough money to last the next year.

    “As a result, the Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that these consolidated financial statements are issued.”
    Show the full paragraph
    The Company has incurred losses and negative cash flows from operations since inception and had an accumulated deficit of $ 161.8 million as of September 30, 2026. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenues from its current or any future product candidates. The Company believes its cash and cash equivalents of $ 34.4 million as of September 30, 2026 are not sufficient to fund its projected operations for a period of at least 12 months from the issuance date of these unaudited condensed consolidated financial statements. As a result, the Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The unaudited condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.

    From the 10-Q filed 10 November 2026, Part I, Item 1. Financial Statements. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.